This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. The goal of the Mayo Clinic CTSA application is to present our vision for the integration and expansion of our innovative clinical and translational research activities, so that a highly functional academic home for clinical and translational research is developed at the Mayo Clinic. This new Center for Clinical and Translational Research (CCTR) will be founded on Mayo's long-standing excellence in and commitment to clinical and translational research, which includes the support of key infrastructure and a commitment to career development. To achieve this goal we describe a comprehensive approach to the key elements of the CTSA RFA and focus on enhancing: 1) Clinical Research Core Resources that provide innovative tools to investigators;2) Career Development and Education Programs that prepare the next generation of investigators;3) Compliance and Regulatory Affairs Support that ensures patient safety and privacy, and customer service-oriented approaches to support investigative teams;4) Community Affairs support to enhance participation, diversity and community support for clinical and translational research;5) Collaboration with Industry and Clinical Practices to translate research discoveries into routine clinical practice;and 6) Continued and Expanded Institutional Support that includes an """"""""academic home"""""""" for clinical and translational research. We also propose a consolidated governance plan that incorporates strong data-driven evaluation of each CCTR element and the program as a whole. In principle, the CTSA program is consistent with the historical, conceptual and philosophical underpinnings of Mayo Clinic, and in this application we clearly articulate our vision of how the overarching and transformative goals of the CTSA program can be met at Mayo. Additionally, we have the """"""""institutional will"""""""" and are culturally empowered to execute our plan. Thus, Mayo is ready to implement the CTSA program aggressively and rapidly;the Mayo Clinic CCTR will be a highly functional and successful """"""""flagship"""""""" site for the CTSA program as it emerges from the NIH Roadmap. To summarize, the Mayo Clinic Center for Clinical and Translational Research (CCTR) will bring together all the resources of the five schools within the Mayo Clinic College of Medicine, and more than 100 years of scientific and medical research expertise, to discover innovative new methods that will speed the translation of research results into therapies, tools and patient care practices that impact all members of our local and national communities. This vision is entirely consistent with the stated mission of the Mayo Clinic to provide the best care to every patient every day.through integrated clinical practice, education and research.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1RR024150-05
Application #
8175541
Study Section
Special Emphasis Panel (ZRR1-CR-A (01))
Project Start
2010-07-01
Project End
2011-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
5
Fiscal Year
2010
Total Cost
$3,385,130
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Ogaki, Kotaro; Martens, Yuka A; Heckman, Michael G et al. (2018) Multiple system atrophy and apolipoprotein E. Mov Disord 33:647-650
Herrmann, Sandra M; Textor, Stephen C (2018) Current Concepts in the Treatment of Renovascular Hypertension. Am J Hypertens 31:139-149
Cundrle Jr, Ivan; Somers, Virend K; Singh, Prachi et al. (2018) Low leptin concentration may identify heart failure patients with central sleep apnea. J Sleep Res 27:240-243
McKenzie, Katelyn A; El Ters, Mirelle; Torres, Vicente E et al. (2018) Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrol 19:378
Dad, Taimur; Abebe, Kaleab Z; Bae, K Ty et al. (2018) Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep 3:619-624
Watters, Julie T; Pitzen, Jason H; Sanders, Linda J et al. (2018) Transforming the Activation of Clinical Trials. Clin Pharmacol Ther 103:43-46
Levendowski, Daniel J; St Louis, Erik K; Strambi, Luigi Ferini et al. (2018) Comparison of EMG power during sleep from the submental and frontalis muscles. Nat Sci Sleep 10:431-437
Berti, Alvise; Warner, Roscoe; Johnson, Kent et al. (2018) Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 70:1114-1121
Chung, Jin Ook; Koutsari, Christina; Blachnio-Zablieska, Agnieszka Urszula et al. (2018) Effects of meal ingestion on intramyocellular ceramide concentrations and fractional de novo synthesis in humans. Am J Physiol Endocrinol Metab 314:E105-E114
Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2018) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 93:691-699

Showing the most recent 10 out of 1084 publications